Skip to main content
Log in

Risk stratification and prevention of sudden death in hypertrophic cardiomyopathy

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Sudden cardiac death is the most devastating manifestation of hypertrophic cardiomyopathy (HCM) and often occurs in young and previously asymptomatic patients. Therefore, risk stratification for sudden death has a major role in the management of HCM and has acquired even greater relevance since the implantable cardioverter-defibrillator (ICD) has proved to be highly effective in preventing sudden death in this disease. The ICD is definitely indicated for secondary prevention of sudden death in patients with HCM who have survived a cardiac arrest with documented ventricular fibrillation, or experienced one or more episodes of sustained ventricular tachycardia. However, uncertainties persist regarding the precise selection of patients for primary prophylactic ICD implantation. A number of risk markers are used to assess the magnitude of risk, including family history of premature sudden death; extreme left ventricular (LV) hypertrophy (> 30 mm) in young patients; nonsustained ventricular tachycardia on Holter electrocardiographic recording; unexplained (not neurally mediated) syncope, particularly in young patients; and blood pressure decrease or inadequate increase during upright exercise. Multiple risk factors convey a definite increase in risk. However, a single risk factor such as family history of multiple sudden deaths, massive LV hypertrophy in a young patient, or frequent and/or prolonged runs of nonsustained ventricular tachycardia on Holter, may also justify consideration of a prophylactic ICD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Maron BJ, McKenna WJ, Danielson GK, et al.: American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003, 42:1687–1713.

    Article  PubMed  Google Scholar 

  2. Spirito P, Seidman CE, McKenna WJ, Maron BJ: The management of hypertrophic cardiomyopathy. N Engl J Med 1997, 336:775–785.

    Article  PubMed  CAS  Google Scholar 

  3. Maron BJ: Hypertrophic cardiomyopathy. A systematic review. JAMA 2002, 287:1308–1320.

    Article  PubMed  Google Scholar 

  4. Elliott P, McKenna WJ: Hypertrophic cardiomyopathy. Lancet 2004, 363:1881–1891.

    Article  PubMed  CAS  Google Scholar 

  5. Spirito P, Autore C: Management of hypertrophic cardiomyopathy. BMJ 2006, 332:1251–1255.

    Article  PubMed  Google Scholar 

  6. Moon JCC, McKenna WJ, McCrohon JA, et al.: Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003, 41:1561–1567.

    Article  PubMed  Google Scholar 

  7. Carsten R, Norbert MW, Michael JH, et al.: Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005, 112:855–861.

    Article  Google Scholar 

  8. Seidman JG, Seidman C: The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001, 104:557–567.

    Article  PubMed  CAS  Google Scholar 

  9. Arad M, Maron BJ, Gorham JM, et al.: Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005, 352:362–372.

    Article  PubMed  CAS  Google Scholar 

  10. Maron BJ, Shen WK, Link MS, et al.: Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000, 342:365–373.

    Article  PubMed  CAS  Google Scholar 

  11. Maron BJ, Spirito P, Shen WK, et al.: Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007, 298:405–412.

    Article  PubMed  CAS  Google Scholar 

  12. Spirito P, Bellone P, Harris KM, et al.: Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000, 342:1778–1785.

    Article  PubMed  CAS  Google Scholar 

  13. Elliott PM, Gimeno B Jr, Mahon NG, et al.: Relation between severity of left ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001, 357:420–424.

    Article  PubMed  CAS  Google Scholar 

  14. Monserrat L, Elliott PM, Gimeno JR, et al.: Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003, 42:873–879.

    Article  PubMed  Google Scholar 

  15. Sadoul N, Prasad K, Elliott PM, et al.: Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997, 96:2987–2991.

    PubMed  CAS  Google Scholar 

  16. Maron MS, Olivotto I, Betocchi S, et al.: Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003, 348:295–303.

    Article  PubMed  Google Scholar 

  17. Elliott PM, Poloniecki J, Dickie S, et al.: Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000, 36:2212–2218.

    Article  PubMed  CAS  Google Scholar 

  18. Maron BJ, Mark Estes NA, Maron MS, et al.: Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation 2003, 107:2872–2875.

    Article  PubMed  Google Scholar 

  19. Spirito P, Maron BJ, Bonow RO, et al.: Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol 1987, 60:123–129.

    Article  PubMed  CAS  Google Scholar 

  20. Biagini E, Coccolo F, Ferlito M, et al.: Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 2005, 46:1543–1550.

    Article  PubMed  Google Scholar 

  21. Harris KM, Spirito P, Maron MS, et al.: Prevalence, clinical profile and significance of the end-stage phase in a large hypertrophic cardiomyopathy cohort. Circulation 2006, 114:216–225.

    Article  PubMed  Google Scholar 

  22. Boriani G, Maron BJ, Shen WK, Spirito P: Prevention of sudden death in hypertrophic cardiomyopathy. But which defibrillator for which patient? Circulation 2004, 110:e438–e442.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paolo Spirito.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Autore, C., Quarta, G. & Spirito, P. Risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Curr Treat Options Cardio Med 9, 431–435 (2007). https://doi.org/10.1007/s11936-007-0037-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-007-0037-y

Keywords

Navigation